Deepak Tiwari
Keine laufenden Positionen mehr
Karriereverlauf von Deepak Tiwari
Ehemalige bekannte Positionen von Deepak Tiwari
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Corporate Officer/Principal | - | - |
| GLYCOMIMETICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 02.03.2022 | - |
Ausbildung von Deepak Tiwari
| St. John's University | Doctorate Degree |
| University of Delhi | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 4 |
| Indien | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 2 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GLYCOMIMETICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
- Börse
- Insiders
- Deepak Tiwari
- Erfahrung
